Alternative splicing changes as drivers of cancer

Alternative splicing changes are frequently observed in cancer and are starting to be recognized as important signatures for tumor progression and therapy. However, their functional impact and relevance to tumorigenesis remains mostly unknown. We carried out a systematic analysis to characterize the potential functional consequences of alternative splicing changes in thousands of tumor samples. This analysis reveals that a subset of alternative splicing changes affect protein domain families that are frequently mutated in tumors, potentially disrupt protein-protein interactions in cancer-related pathways, and are mutually exclusive with mutations in multiple cancer drivers. Moreover, there is a negative correlation between the number of these alternative splicing changes in a sample and the number of somatic mutations in drivers. We propose that a subset of the alternative splicing changes observed in tumors represents independent oncogenic processes and could potentially be considered alternative splicing drivers (AS-drivers).

[1]  Alexander Lex,et al.  UpSetR: an R package for the visualization of intersecting sets and their properties , 2017, bioRxiv.

[2]  Leonard D. Goldstein,et al.  Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers. , 2016, Cell reports.

[3]  Omar Abdel-Wahab,et al.  Therapeutic targeting of splicing in cancer , 2016, Nature Medicine.

[4]  Y. Xing,et al.  SURVIV for survival analysis of mRNA isoform variation , 2016, Nature Communications.

[5]  K. Brown,et al.  A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. , 2016, Cell reports.

[6]  E. Eyras,et al.  The prognostic potential of alternative transcript isoforms across human tumors , 2016, Genome Medicine.

[7]  J. Valcárcel,et al.  Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks , 2016, Genome research.

[8]  S. Roman-Roman,et al.  Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage , 2016, Nature Communications.

[9]  Gloria M. Sheynkman,et al.  Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing , 2016, Cell.

[10]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[11]  L. Shkreta,et al.  Defective control of pre–messenger RNA splicing in human disease , 2016, The Journal of cell biology.

[12]  Robert D. Finn,et al.  The Pfam protein families database: towards a more sustainable future , 2015, Nucleic Acids Res..

[13]  Zhongming Zhao,et al.  TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes , 2015, Nucleic Acids Res..

[14]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[15]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[16]  M. Warmuth,et al.  Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. , 2015, Cell reports.

[17]  Yeon Jeong Kim,et al.  Intron retention is a widespread mechanism of tumor-suppressor inactivation , 2015, Nature Genetics.

[18]  Shuying Sun,et al.  SRSF1-Regulated Alternative Splicing in Breast Cancer. , 2015, Molecular cell.

[19]  Chris Sander,et al.  Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. , 2015, Cell systems.

[20]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[21]  Gael P. Alamancos,et al.  Leveraging transcript quantification for fast computation of alternative splicing profiles , 2014, bioRxiv.

[22]  Michael Q. Zhang,et al.  Differential connectivity of splicing activators and repressors to the human spliceosome , 2015, Genome Biology.

[23]  J. Yokota,et al.  Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. , 2015, Cancer research.

[24]  H. Dvinge,et al.  Widespread intron retention diversifies most cancer transcriptomes , 2015, Genome Medicine.

[25]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[26]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[27]  E. Levanon,et al.  Identification of recurrent regulated alternative splicing events across human solid tumors , 2015, Nucleic acids research.

[28]  T. Misteli,et al.  Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing , 2015, Nature Communications.

[29]  Fan Yang,et al.  Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations , 2015, PLoS Comput. Biol..

[30]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[31]  Eduardo Eyras,et al.  Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer , 2015, Nucleic acids research.

[32]  S. Miyano,et al.  Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome , 2014, Nature Communications.

[33]  Kara Dolinski,et al.  The BioGRID interaction database: 2015 update , 2014, Nucleic Acids Res..

[34]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[35]  E. Larsson,et al.  Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types , 2014, Nature Genetics.

[36]  Bridget E. Begg,et al.  A Proteome-Scale Map of the Human Interactome Network , 2014, Cell.

[37]  C. Sander,et al.  Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations , 2014, Genome Biology.

[38]  Yi Xing,et al.  Transcriptome-wide Landscape of Pre-mRNA Alternative Splicing Associated with Metastatic Colonization , 2014, Molecular Cancer Research.

[39]  M. Ares,et al.  Context-dependent control of alternative splicing by RNA-binding proteins , 2014, Nature Reviews Genetics.

[40]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[41]  David Tamborero,et al.  OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action , 2014, Bioinform..

[42]  Monika Heiner,et al.  The RNA-Binding Protein QKI Suppresses Cancer-Associated Aberrant Splicing , 2014, PLoS genetics.

[43]  J. Valcárcel,et al.  Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers , 2014, Cell.

[44]  Matthew Fraser,et al.  InterProScan 5: genome-scale protein function classification , 2014, Bioinform..

[45]  Robert D. Finn,et al.  iPfam: a database of protein family and domain interactions found in the Protein Data Bank , 2013, Nucleic Acids Res..

[46]  Baldomero Oliva,et al.  ArchDB 2014: structural classification of loops in proteins , 2013, Nucleic Acids Res..

[47]  Arnaud Céol,et al.  3did: a catalog of domain-based interactions of known three-dimensional structure , 2013, Nucleic Acids Res..

[48]  J. Valcárcel,et al.  RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. , 2013, Molecular cell.

[49]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[50]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[51]  H. Gautrey,et al.  Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance , 2013, International journal of cell biology.

[52]  Johannes Goll,et al.  A new reference implementation of the PSICQUIC web service , 2013, Nucleic Acids Res..

[53]  Hai Fang,et al.  dcGO: database of domain-centric ontologies on functions, phenotypes, diseases and more , 2012, Nucleic Acids Res..

[54]  S. Licciulli,et al.  The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis , 2012, Oncogene.

[55]  D. Radisky,et al.  Involvement of hnRNP A1 in the matrix metalloprotease‐3‐dependent regulation of Rac1 pre‐mRNA splicing , 2012, Journal of cellular biochemistry.

[56]  Alex Bateman,et al.  Tissue-Specific Splicing of Disordered Segments that Embed Binding Motifs Rewires Protein Interaction Networks , 2012, Molecular cell.

[57]  Xinchen Wang,et al.  Tissue-specific alternative splicing remodels protein-protein interaction networks. , 2012, Molecular cell.

[58]  John A. Calarco,et al.  Emerging Roles of Alternative Pre-mRNA Splicing Regulation in Neuronal Development and Function , 2012, Front. Neurosci..

[59]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[60]  L. Cartegni,et al.  Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. , 2011, Molecular cell.

[61]  E. Marcotte,et al.  Prioritizing candidate disease genes by network-based boosting of genome-wide association data. , 2011, Genome research.

[62]  Eli Upfal,et al.  De Novo Discovery of Mutated Driver Pathways in Cancer , 2011, RECOMB.

[63]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[64]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[65]  Nuria Lopez-Bigas,et al.  IntOGen: integration and data mining of multidimensional oncogenomic data , 2010, Nature Methods.

[66]  T. Cooper,et al.  The pathobiology of splicing , 2010, The Journal of pathology.

[67]  Hans-Werner Mewes,et al.  CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..

[68]  P. Jordan,et al.  Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. , 2009, Human molecular genetics.

[69]  Zsuzsanna Dosztányi,et al.  ANCHOR: web server for predicting protein binding regions in disordered proteins , 2009, Bioinform..

[70]  K. Hansen,et al.  Genome-Wide Identification of Alternative Splice Forms Down-Regulated by Nonsense-Mediated mRNA Decay in Drosophila , 2009, PLoS genetics.

[71]  Hannah H. Chang,et al.  Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours , 2009, Nature Reviews Genetics.

[72]  David Warde-Farley,et al.  Dynamic modularity in protein interaction networks predicts breast cancer outcome , 2009, Nature Biotechnology.

[73]  J. Cheville,et al.  A p120 Catenin Isoform Switch Affects Rho Activity, Induces Tumor Cell Invasion, and Predicts Metastatic Disease* , 2008, Journal of Biological Chemistry.

[74]  Carter T. Butts,et al.  network: A Package for Managing Relational Data in R , 2008 .

[75]  Jean-Loup Guillaume,et al.  Fast unfolding of communities in large networks , 2008, 0803.0476.

[76]  R. Zimmer,et al.  Alternative splicing and protein structure evolution. , 2008, Nucleic acids research.

[77]  Teresa M. Przytycka,et al.  DOMINE: a database of protein domain interactions , 2007, Nucleic Acids Res..

[78]  Aric Hagberg,et al.  Exploring Network Structure, Dynamics, and Function using NetworkX , 2008, Proceedings of the Python in Science Conference.

[79]  J. Bourdon,et al.  p53 and its isoforms in cancer , 2007, British Journal of Cancer.

[80]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[81]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[82]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.

[83]  Ying Xu,et al.  Structural genomics analysis of alternative splicing and application to isoform structure modeling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[84]  Shinichiro Wachi,et al.  Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues , 2005, Bioinform..

[85]  Zsuzsanna Dosztányi,et al.  IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..

[86]  Stefan Stamm,et al.  Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA. , 2004, Human molecular genetics.

[87]  R. Salgia,et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.

[88]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[89]  Amos Bairoch,et al.  ScanProsite: a reference implementation of a PROSITE scanning tool. , 2002, Applied bioinformatics.